leuprolide acetate for depot suspension / Generic mfg.  >>  Phase 3
Welcome,         Profile    Billing    Logout  

31 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
leuprolide acetate for depot suspension / Generic mfg.
Uterine Leiomyoma-7: Phase III study of leuprorelin depot

Ongoing
3
0
RoW
Luphere (3 month depot) (leuprorelin depot)
Daewoong
Uterine Leiomyoma
 
 
Endometriosis & Endometrial Pain-10: Luphere Depot approved for endometriosis

Ongoing
3
0
RoW
Luphere (3 month depot) (leuprorelin depot)
Daewoong
Endometriosis & Endometrial Pain
 
 
2004-001720-21: A Phase III, multi-center, randomized, double-blind comparator study to evaluate the efficacy and safety of 50 mg and 100 mg of TAK-013 tablets administered twice daily versus 3.75mg of Leuprolide administered monthly for 24 weeks in subjects with symptomatic endometriosis.

Ongoing
3
200
Europe
Sufugolix, Leuprorelin acetate, TAK-013, Coated tablet, Powder for suspension for injection, Leuprorelin acetate
Takeda Europe R&D Centre Ltd
Endometriosis
 
 
ChiCTR-IIR-15007521: The efficacy and safety of using mifepristone in the treatment of uterine fibroids: a randomized, multiple-center controlled trial

Completed
3
300
 
Three months of daily therapy with oral mifepristone (at a dose of 10 mg) ;Three months of daily therapy with oral mifepristone (at a dose of 25 mg) ;once-monthly subcutaneous injections of enantone (at a dose of 3.75 mg)
Peking University First Hospital; Peking University First Hospital, CR Zizhu Pharmaceutical Co., Ltd
Uterine fibroids
 
 
RTOG 0534, NCT00567580: Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

Active, not recruiting
3
1792
Canada, US, RoW
PBRT, Prostate bed radiotherapy, Three-Dimensional Conformal Radiation Therapy (3D-CRT), Intensity modulated RT (IMRT), PLNRT, Pelvic lymph node radiotherapy, AA, flutamide, bicalutamide, LHRH agonist, leuprolide, goserelin, buserelin, triptorelin
Radiation Therapy Oncology Group, National Cancer Institute (NCI), Cancer and Leukemia Group B, NRG Oncology
Prostate Cancer
07/18
 
NCT00430183: Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

Active, not recruiting
3
788
Canada, US
docetaxel, LHRH agonist, leuprolide acetate OR, goserelin acetate, surgery
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Eastern Cooperative Oncology Group, NCIC Clinical Trials Group, Southwest Oncology Group
Prostate Cancer
10/18
10/30
NCT00936390 / 2010-020825-42: Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Active, not recruiting
3
1538
Canada, US
bicalutamide, flutamide, anti-androgen therapy, LHRH agonist (antagonist) therapy, leuprolide, goserelin, buserelin, triptorelin, degarelix, Dose-Escalated Radiation Therapy
Radiation Therapy Oncology Group, National Cancer Institute (NCI), NRG Oncology
Prostate Cancer
10/20
10/25
NCT03695237 / 2022-004131-61: A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)

Completed
3
45
US
Leuprolide Acetate (LA), Lupron Depot
AbbVie, AbbVie Inc.
Central Precocious Puberty (CPP)
05/21
11/23
NCT01546987: Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Active, not recruiting
3
239
Canada, US
GnRH agonist, LHRH analog, leuprolide, goserelin, buserelin, triptorelin, Gonadotropin-releasing hormone (GnRH) Agonist, LHRH agonist, Anti-androgen, flutamide, bicalutamide, androgen suppression, TAK-700, Radiation therapy
Radiation Therapy Oncology Group, National Cancer Institute (NCI), NRG Oncology
Prostate Cancer
11/21
06/29
BSV_LEUPR_18_05, NCT04914195: Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer

Completed
3
155
RoW
Leuprolide Acetate 3.75 MG/ML
Bharat Serums and Vaccines Limited
Advanced Prostate Adenocarcinoma
09/22
09/22
S1207, NCT01674140: Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

Active, not recruiting
3
1939
US
anastrozole, Arimidex, everolimus, Afinitor, exemestane, Aromasin, goserelin acetate, Zoladex, letrozole, Femara, leuprolide acetate, Lupron, tamoxifen citrate, nolvadex, placebo
SWOG Cancer Research Network, National Cancer Institute (NCI)
Breast Cancer
12/22
01/30
DELFINO, NCT03664895: Density Lowering Effect of "OFS Add on to TMX"( Trial)

Recruiting
3
224
RoW
Leuplin or zoladex
Seoul National University Hospital
Breast Cancer Invasive
12/24
12/24
ENDOSafe, NCT06145438: Comparing the Safety and Efficacy in the Use of Hormonal Therapy on Endometriosis Patients After Conservative Surgery

Recruiting
3
100
RoW
Dienogest, Nelandoz, Depo Medroxyprogesterone acetate, Depo Provera, Leuprolide (as Leuprolide Acetate), Tapros, Levonogestrel + etinilestradiol (30 mcg, brand name Mycrogynon), Combined oral contraceptive
Universitas Diponegoro
Endometriosis Ovary
03/24
04/24
NCT05169112: Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy

Recruiting
3
40
Canada
Lupron Depot
Ottawa Hospital Research Institute
Prostate Cancer
11/23
11/28
URONCOR 06-24, NCT05781217 / 2021-006975-41: Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624

Recruiting
3
534
Europe
triptorelin, goserelin, leuprorelin
Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic, GICOR
Prostate Cancer, Salvage Radiotherapy, Biochemical Recurrence, Androgen Deprivation Therapy, Metastases-free Survival
12/23
12/32
ASPAIT, NCT02914158: Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women

Recruiting
3
680
RoW
Goserelin, Tamoxifen, Aromatase Inhibitors, Leuprolide, leuprolide acetate
First Affiliated Hospital, Sun Yat-Sen University
Breast Cancer
12/23
12/25
NCT06397703: ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer

Recruiting
3
392
US
Leuprolide, Degarelix or Relugolix, Stereotactic body radiation therapy/radiosurgery (SBRT)
NYU Langone Health
Prostate Cancer
04/28
04/28
CASPAR, NCT04455750: A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy

Active, not recruiting
3
61
US
Enzalutamide, Rucaparib camsylate, Placebo, Leuprolide Acetate, Goserelin Acetate, Degarelix, Quality-of-Life Assessment, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
05/24
09/26
NCT06490328: Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer

Recruiting
3
154
RoW
DKF-MA102, Leuprorelin acetate
Dongkook Pharmaceutical Co., Ltd.
Advanced Prostate Cancer
05/25
05/25
GenSci093-301, NCT06449027: Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.

Not yet recruiting
3
200
RoW
T Leuprolide Injectable Emulsion, Tamoxifen Citrate Tablets, Leuprorelin Acetate Microspheres for Injection
Changchun GeneScience Pharmaceutical Co., Ltd.
Breast Cancer Subjects
11/25
03/26
PRESTO, NCT03009981: A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

Active, not recruiting
3
504
US
Apalutamide, Erleada, LHRH Analogue, Degarelix (Firmagon), Leuprolide (Lupron) and Bicalutamide, Abiraterone Acetate, Zytiga, Prednisone, Deltasone
Alliance Foundation Trials, LLC., Janssen Research & Development, LLC
Prostate Cancer
07/25
01/26
DETECT V, NCT02344472 / 2014-002249-22: Detect V / CHEVENDO (Chemo vs. Endo)

Active, not recruiting
3
271
Europe
pertuzumab, Perjeta®, Trastuzumab, Herceptin®, Capecitabine, Paclitaxel, Vinorelbine, Docetaxel, Exemestane, Letrozole, Anastrozole, Fulvestrant, Ribociclib, Kisqali®, nab-Paclitaxel, eribulin, leuprorelin, goserelin
Prof. Wolfgang Janni, Roche Pharma AG, Novartis Pharmaceuticals, Eisai GmbH, Celgene Corporation
Metastatic Breast Cancer
01/25
01/25
NCT06025409: Evaluate the Efficacy and Safety of DWJ108J

Recruiting
3
79
RoW
Leuprolide Acetate 11.25 MG/ML
Daewoong Pharmaceutical Co. LTD.
Central Precocious Puberty
02/25
08/25
NCT05440383: A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia

Active, not recruiting
3
264
Japan
KLH-2109, Leuprorelin
Kissei Pharmaceutical Co., Ltd.
Uterine Fibroids (MeSH Heading: Leiomyoma)
05/25
05/25
NCT01492972: Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer

Recruiting
3
192
US
Radiation, Androgen Suppression Therapy, leuprolide, goserelin, buserelin, or triptorelin
Proton Collaborative Group
Prostate Cancer
12/25
 
REPLACE-CV, NCT05605964: Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate

Active, not recruiting
3
2250
US
Relugolix, ORGOVYX, TAK-385, MVT-601, RVT-601, T-1331285, Leuprolide Acetate, Leuprolide
Sumitomo Pharma Switzerland GmbH
Prostate Cancer
12/24
12/24
ADJUVANT WIDER, NCT05827081: Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Suspended
3
3100
RoW
Ribociclib, Letrozole, Ansastrozole, Goserelin, Leuprolide, Exemestane
Novartis Pharmaceuticals
Early Breast Cancer
09/29
09/30
CARLHA-2, NCT04181203: Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy

Recruiting
3
490
Europe
Apalutamide, ARN-509, Salvage radiotherapy (SRT), Luteinising Hormone Releasing Hormone agonist (LHRHa), leuprolide, goserelin, triptorelin acetate
UNICANCER, Janssen Pharmaceutica
Prostate Cancer
09/28
12/33
GUIDANCE, NCT05050084: Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score

Recruiting
3
2050
Canada, US
Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Buserelin, 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig), BSRL, Busereline, Etilamide, HOE 766, ICI 123215, S74-6766, Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, Nubeqa, ODM 201, ODM-201, Degarelix, FE200486, Firmagon, Flutamide, 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, Sch 13521, Tafenil, Tecnoflut, Testotard, Goserelin, ICI-118630, Histrelin, Leuprolide, Leuprorelin, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Relugolix, N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea, Orgovyx, TAK 385, TAK-385, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Detryptoreline
NRG Oncology, National Cancer Institute (NCI)
Prostate Adenocarcinoma
04/32
04/37
PREDICT-RT, NCT04513717: Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The Trial

Recruiting
3
2478
Canada, US
Apalutamide, ARN 509, ARN-509, ARN509, Erleada, JNJ 56021927, JNJ-56021927, Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Buserelin, 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig), BSRL, Busereline, Etilamide, HOE 766, ICI 123215, S74-6766, Degarelix, FE200486, Firmagon, Flutamide, 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, Sch 13521, Tafenil, Tecnoflut, Testotard, Goserelin, ICI-118630, Histrelin, Leuprolide, Leuprorelin, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Detryptoreline
NRG Oncology, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Bone, Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
12/33
12/33
VA STARPORT, NCT04787744: Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

Recruiting
2/3
464
US
PET-directed Local Therapy using Surgery, PET-directed Local Therapy using Radiation, Salvage Local Therapy for locally recurrent disease, Goserelin, Histrelin, Leuprolide & Triptorelin, ADT + Nilutamide, Flutamide, & Bicalutamide, Degarelix & Relugolix, ADT + Docetaxel +/- prednisone, ADT + Abiraterone + Prednisone, ADT + Abiraterone + Methylprednisolone, ADT + Apalutamide, ADT + Enzalutamide, Prostate-directed Radiation for De novo oligometastatic prostate cancer
VA Office of Research and Development
Prostate Cancer, Oligometastasis, Oligorecurrence, Recurrent Prostate Cancer, Metastatic Prostate Cancer, De Novo Prostate Cancer
07/25
12/25

Download Options